[go: up one dir, main page]

AR101811A1 - Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular - Google Patents

Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular

Info

Publication number
AR101811A1
AR101811A1 ARP150102894A ARP150102894A AR101811A1 AR 101811 A1 AR101811 A1 AR 101811A1 AR P150102894 A ARP150102894 A AR P150102894A AR P150102894 A ARP150102894 A AR P150102894A AR 101811 A1 AR101811 A1 AR 101811A1
Authority
AR
Argentina
Prior art keywords
monoclonal antibody
enzymatic activity
humanized monoclonal
lipase
antibody inhibiting
Prior art date
Application number
ARP150102894A
Other languages
English (en)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55459146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR101811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of AR101811A1 publication Critical patent/AR101811A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo monoclonal humanizado, o un fragmento de este, que inhibe de manera selectiva la actividad enzimática de la lipasa endotelial vascular, y composiciones farmacéuticas que lo contienen como ingrediente activo, útiles para el tratamiento de la arterioesclerosis o el síndrome metabólico. Reivindicación 1: Un anticuerpo monoclonal humanizado caracterizado porque inhibe la actividad enzimática de la lipasa endotelial vascular, o un fragmento de anticuerpo de aquel, en donde aquel reconoce residuos de aminoácidos en las posiciones 1 a 157 en la secuencia de aminoácidos de SEQ ID Nº 1.
ARP150102894A 2014-09-11 2015-09-10 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular AR101811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014184710 2014-09-11

Publications (1)

Publication Number Publication Date
AR101811A1 true AR101811A1 (es) 2017-01-11

Family

ID=55459146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102894A AR101811A1 (es) 2014-09-11 2015-09-10 Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular

Country Status (18)

Country Link
US (2) US10570215B2 (es)
EP (1) EP3192813A4 (es)
JP (2) JP6635599B2 (es)
KR (1) KR102520286B1 (es)
CN (1) CN107074963B (es)
AR (1) AR101811A1 (es)
AU (1) AU2015313179B2 (es)
CA (1) CA2960994C (es)
CL (1) CL2017000595A1 (es)
EA (1) EA036324B1 (es)
IL (1) IL250981B (es)
MX (1) MX388559B (es)
MY (1) MY181835A (es)
PH (1) PH12017500461B1 (es)
SG (2) SG10201900605SA (es)
TW (2) TWI688575B (es)
WO (1) WO2016039402A1 (es)
ZA (1) ZA201702489B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890158A1 (ru) * 2015-06-30 2018-06-29 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные композиции и способы
CN111263769B (zh) * 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
WO2019091449A1 (zh) * 2017-11-10 2019-05-16 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
CA3192235A1 (en) * 2019-11-07 2021-05-14 Medimmune, Llc Endothelial lipase antibodies for the treatment of cardiovascular diseases
CA3211692A1 (en) * 2020-02-24 2023-09-02 Medimmune, Llc Formulations of anti-endothelial lipase antibodies
US20240092897A1 (en) * 2020-11-05 2024-03-21 Shanghai Jmt-Bio Technology Co., Ltd. Anti-siglec-15 antibody and application thereof in preparing drug
WO2025111317A1 (en) * 2023-11-21 2025-05-30 The Brigham And Women's Hospital, Inc. Klrb1 binding agents and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062075B2 (ja) * 1988-04-30 1994-01-12 大日本製薬株式会社 抗ヒトポストヘパリンプラズマ由来リポ蛋白リパーゼモノクローナル抗体およびその製造方法
EP0948609B1 (en) * 1996-12-06 2005-03-16 Aventis Pharmaceuticals Inc. Llg polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
WO1999032611A1 (en) * 1997-12-19 1999-07-01 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
MXPA01009727A (es) 1999-03-26 2002-07-22 Aventis Pharma Inc Composiciones y metodos para afectar los niveles de colesterol asociado a lipoproteina de alta densidad (hdl) y a apolipoproteina a1, colesterol asociado a lipoproteina de muy baja densidad (vldl) y colesterol asociado a lipoproteina de baja densidad
JP6195306B2 (ja) * 2011-10-12 2017-09-13 塩野義製薬株式会社 Ｅｌの酵素活性を阻害するｅｌに対するモノクローナル抗体
BR112015022009A2 (pt) * 2013-03-14 2017-08-29 Shionogi & Co Anticorpo monoclonal, inibindo a atividade enzimática de lipase endotelial vascular

Also Published As

Publication number Publication date
JPWO2016039402A1 (ja) 2017-06-22
KR102520286B1 (ko) 2023-04-10
TW202026313A (zh) 2020-07-16
TW201613982A (en) 2016-04-16
TWI734410B (zh) 2021-07-21
CA2960994A1 (en) 2016-03-17
PH12017500461A1 (en) 2017-07-31
SG10201900605SA (en) 2019-02-27
US20200071424A1 (en) 2020-03-05
JP2020059743A (ja) 2020-04-16
SG11201701762VA (en) 2017-04-27
JP6827255B2 (ja) 2021-02-10
MX2017002968A (es) 2017-06-15
IL250981B (en) 2020-06-30
JP6635599B2 (ja) 2020-01-29
TWI688575B (zh) 2020-03-21
IL250981A0 (en) 2017-04-30
ZA201702489B (en) 2018-08-29
CL2017000595A1 (es) 2017-11-03
EA201790590A1 (ru) 2017-08-31
MY181835A (en) 2021-01-08
US11136411B2 (en) 2021-10-05
CN107074963B (zh) 2021-07-16
CA2960994C (en) 2025-07-08
EA036324B1 (ru) 2020-10-27
AU2015313179A1 (en) 2017-03-30
BR112017004429A2 (pt) 2018-02-27
MX388559B (es) 2025-03-20
EP3192813A1 (en) 2017-07-19
US10570215B2 (en) 2020-02-25
KR20170052655A (ko) 2017-05-12
AU2015313179B2 (en) 2020-10-22
CN107074963A (zh) 2017-08-18
US20170260290A1 (en) 2017-09-14
PH12017500461B1 (en) 2023-07-19
EP3192813A4 (en) 2018-08-01
WO2016039402A1 (ja) 2016-03-17

Similar Documents

Publication Publication Date Title
AR101811A1 (es) Anticuerpo monoclonal humanizado que inhibe la actividad enzimática de la lipasa endotelial vascular
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
MX389228B (es) Composiciones para tratar el cabello.
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
EP3530123A4 (en) COMPOSITION OF ANIMAL FEED CONTAINING A SUBTLE BACILIUS STRAIN AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING ACUTE HEPATOPANCREATIC NECROSIS DISEASE OR WHITE SPOT SYNDROME
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
MX385401B (es) Composiciones que contienen lipo-quitooligosacarido y microorganismo para potenciar el crecimiento de las plantas.
MX2017008561A (es) Novedoso bacteriófago clo-pep-1 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens.
DK3334444T3 (da) Sammensætning af mælkesyrebakterier til anvendelse i behandling af infektioner, der skyldes propionibacterium acnes, og navnlig til acne
MX2019006893A (es) Inhibidores heterociclicos de mct4.
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
EA201791716A1 (ru) Фармацевтический состав
BR112016023519A2 (pt) inibidor de sinalização de wnt/ß-catenina, composição farmacêutica e método de tratamento e/ou prevenção de uma patologia definida por malformação vascular
UY38352A (es) Inhibidores de integrina alfavbeta6
EP3292872C0 (en) Composition for treatment or prevention of infectious inflammatory disease, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as active ingredient
PH12016502000B1 (en) Novel bacteriophage and composition comprising same
CL2015002642A1 (es) Anticuerpo monoclonal, inhibiendo la actividad enzimática de la lipasa endotelial vascular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal